Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

Fig. 2

NK cells and DCs rapidly respond to laquinimod therapy. a Graphs show the mean fluorescence intensity (MFI) of activating NK cell markers as calculated from flow cytometry data at different time points. Cells were derived from laquinimod- or vehicle-treated MOG35–55-immunized animals. Data are presented as mean ± S.E.M. and are representative of four independent experiments with three animals per group and time point. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired t test. b Representative flow cytometry analysis of MHC class II/CD11c expression in the spleens of laquinimod- or vehicle-treated animals. Frequency of MHC class II+ CD11chigh cells in the spleens of laquinimod- or vehicle-treated animals immunized with MOG35–55 as calculated from flow cytometry data at different time points. c MFI of CD80 and CD86 staining on splenic DCs of laquinimod- or vehicle-treated MOG35–55-immunized animals at different time points. Data are presented as mean ± S.E.M. and are representative of two independent experiments with three animals/group and time point. *P < 0.05, **P < 0.01, unpaired t test

Back to article page